Table 1.
Patient Demographics: Exploration Cohort
| Parameter | Total (n = 754) | SSRI/SNRI+ (n = 71) | SSRI− (n = 683) | P |
|---|---|---|---|---|
| Median (Range), n (%) | Median (Range), n (%) | Median (Range), n (%) | ||
| Gender | 0.124 | |||
| Male | 457 (60.6%) | 37 (52.1%) | 420 (61.5%) | |
| Female | 297(39.4%) | 34 (47.9%) | 263 (38.5%) | |
| Age (years) | 63 (20‐89) | 65 (25‐83) | 63 (20‐89) | 0.628 |
| Hepatic resection | 0.586 | |||
| Minor (<3 segments) | 363 (48.1%) | 32 (45.1%) | 331 (48.5%) | |
| Major (≥3 segments) | 391 (51.9%) | 39 (54.9%) | 352 (51.5%) | |
| Tumor type | 0.117 | |||
| CRLM | 473 (62.7%) | 36 (50.7%) | 437 (64.0%) | |
| HCC | 99 (13.1%) | 10 (14.1%) | 89 (13.0%) | |
| CCC | 123 (16.3%) | 14 (19.7%) | 109 (16.0%) | |
| Benign | 30 (4.0%) | 2 (6.7%) | 28 (4.1%) | |
| Other | 29 (3.8%) | 9 (12.7%) | 20 (2.9%) | |
| Cofactors | ||||
| Steatosis (%) | 5.00 (0‐100) | 0.00 (0‐80) | 5.00 (0‐100) | 0.024 |
| Fibrosis | 0.304 | |||
| F0 | 312 (46.4%) | 25 (39.1%) | 287 (47.1%) | |
| F1 | 216 (32.1%) | 20 (31.3%) | 196 (32.2%) | |
| F2 | 73 (10.8%) | 11 (17.2%) | 62 (10.2%) | |
| F3 | 30 (4.5%) | 2 (3.1%) | 28 (4.6%) | |
| F4/cirrhosis | 42 (6.2%) | 6 (9.4%) | 36 (5.9%) | |
| Intraoperative RBC | 0 (0‐28) | 0 (0‐14) | 0(0‐28) | 0.537 |
| Pringle applied | 82 (12.5%) | 7 (12.5%) | 75 (12.5%) | 0.563 |
| PVE | 45 (7.3%) | 6 (11.1%) | 39 (6.9%) | 0.260 |
| Comorbidities | ||||
| Cardiovascular | 72 (10.9%) | 8 (13.6%) | 64 (10.6%) | 0.488 |
| Pulmonary | 43 (6.4%) | 4 (6.5%) | 39 (6.4%) | 0.994 |
| Renal | 13 (1.9%) | 3 (4.8%) | 10 (1.6%) | 0.078 |
| Diabetes | 82 (12.0%) | 6 (9.5%) | 76 (12.2.%) | 0.527 |
| Obesity | 159 (22.7%) | 9 (14.3%) | 150 (23.5%) | 0.095 |
| Preoperative parameters | ||||
| SB (mg/dL) | 0.62 (0.14‐18.5) | 0.58 (0.14‐2.01) | 0.62 (0.15‐18.5) | 0.215 |
| PT (%) | 103 (39‐150) | 101.5 (61‐150) | 104 (39‐150) | 0.441 |
| AP (U/L) | 98.5 (14‐2,005) | 92.0 (38‐936) | 99.5 (38‐936) | 0.209 |
| GGT (U/L) | 58 (7‐2,055) | 53.5 (7‐1,163) | 58 (8‐2,055) | 0.752 |
| AST (U/L) | 30 (5‐615) | 32 (8‐297) | 29 (5‐615) | 0.510 |
| ALT (U/L) | 26 (2‐497) | 30 (5‐279) | 26 (2‐497) | 0.367 |
| Albumin (g/L) | 42 (21‐54) | 41.0 (31‐48) | 42.0 (21‐54) | 0.175 |
| Platelets (G/L) | 201 (43‐678) | 211 (60‐471) | 200 (43‐679) | 0.988 |
| Morbidity | ||||
| None | 445 (59.4%) | 37 (52.1%) | 408 (60.2%) | |
| Any grade | 304 (40.6%) | 34 (47.9%) | 270 (39.8%) | 0.188 |
| Severe | 163 (21.8%) | 22 (31.0%) | 141 (20.8%) | 0.048 |
| Posthepatectomy hemorrhage | ||||
| ISGLS C | 24 (3.5%) | 3 (4.8%) | 21 (3.4%) | 0.380 |
| LD ISGLS | ||||
| No LD | 661 (87.7%) | 56 (78.9%) | 605 (88.6%) | |
| All grades | 93 (12.3%) | 15 (21.1%) | 78 (11.4%) | 0.018 |
| Grade C | 29 (3.8%) | 6 (8.5%) | 23 (3.4%) | 0.034 |
Bold indicates significance.
Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; GGT, gamma‐glutamyl transpeptidase; RBC, red blood cells.